Navigation Links
New Device Developed For Treating Cervical Spondylitis

A neurosurgeon here claims to have developed a device to facilitate keyhole surgery for cervical spondylitis and disk prolapse, in what is being regarded as a breakthrough in spinal treatment. //

Ravi Dev, a young associate professor in the department of neurosurgery at King George's Medical University (KGMU), has developed a unique vertebral drill that he says will save patients from the complicated and painful procedures practised so far.

The central commerce ministry has awarded a patent for the instrument, which facilitates a small hole near the neck to correct a prolapsed disk or provide relief to a patient of acute spondylitis.

"The production of this instrument has been undertaken by a well known private manufacturer and would create a revolution in spinal surgery," Dev told IANS here.

"In both spondylitis and prolapsed disk, it is the compression of the disk that leads to pressure on nerves or the spinal cord and hence causes pain to the patient. This new technique will help to clear that compression without wide incisions or deep invasion."

The procedure is a major step forward from the Cloward technique developed by German scientist R.B. Cloward in 1957.

"The world over, the same technique has been in use," said Dev. "That is a very cumbersome procedure involving a wide incision of at least 8-10 cm. But the new technique requires only a small, two to three centimetre incision and is also much less invasive as the drilling of a tunnel along the disk is done with greater precision under the eye of a microscope," he points out.

"Earlier, the drilling was followed by the hammering of nails into the vertebra and that too with the naked eye, thereby leaving scope for inaccurate and often extra removal of the osteophyte growth along the disk," he said.

"Under the new microscope monitored surgery, the task is far more precise and close to perfection," he added.

"A cap fi
'"/>




Page: 1 2

Related medicine news :

1. Injection supports Heart Devices
2. New Heart-Screening Device ,An Accurate Predictor Of Heart Disease
3. Government Organisation Proposes Strict Guidelines For SubStandard Medical Devices
4. Withdrawal Notice Issued For Older Pacemakers Due To Malfunctioning of the Device
5. New Implantable Device That Can Keep The Heart Ticking
6. Making MRIs Safe for Patients With Implantable Heart Devices
7. Researchers Develop Device For Detecting Atherosclerotic Plaques
8. A Cheap Device to Stop Snoring from New Zealand
9. Scientists Concerned Over Increasing Malfunction Of Heart Devices
10. Device For Improving Bone Mass In Osteoporosis
11. Anti-Microbial Coating For Use Over Biomedical Devices Developed
Post Your Comments:
Breaking Medicine Technology:FDA Launches Orphan Drug Workshop at KGI 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6Research Compares MENOPUR 28R 29 With rFSH in GnRH Antagonist IVF Cycles 5586 1Research Compares MENOPUR 28R 29 With rFSH in GnRH Antagonist IVF Cycles 5586 2Research Compares MENOPUR 28R 29 With rFSH in GnRH Antagonist IVF Cycles 5586 3Clues to Hypertension in Kids May Be Seen in Bones 59798 1Clues to Hypertension in Kids May Be Seen in Bones 59798 2Detailed Results from RV 144 HIV Vaccine Trial Published Today in The New England Journal of Medicine and Presented at the AIDS Vaccine 2009 Conferenc 59795 1Detailed Results from RV 144 HIV Vaccine Trial Published Today in The New England Journal of Medicine and Presented at the AIDS Vaccine 2009 Conferenc 59795 2Detailed Results from RV 144 HIV Vaccine Trial Published Today in The New England Journal of Medicine and Presented at the AIDS Vaccine 2009 Conferenc 59795 3
Other Medicine Technology:Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 2Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 3Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 4Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 5Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 6Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 7Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 8Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 2Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 3Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 4Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 5Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 6